Factors affecting relative dose intensity in patients with Hodgkin lymphoma (HL) receiving doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) without granulocyte-colony stimulating factor (G-CSF) support

被引：0
|
作者：
Kirui, L. C. [1 ]
Cwynarski, K. [1 ]
McNamara, C. [1 ]
机构：
[1] Royal Free Hosp, Dept Haematol, London NW3 2QG, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
135
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [41] Recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with promace-cytabom for HIV-related non-Hodgkin's lymphoma (NHL)
    Rossi, G
    Re, A
    Donisi, A
    Casari, S
    Stellini, R
    Cadeo, GP
    Carosi, GP
    BLOOD, 1995, 86 (10) : 3721 - 3721
  • [42] Febrile Neutropenia (FN) in Early Breast Cancer Patients Receiving FEC-D - the Effect of Moving to Primary Granulocyte-colony Stimulating Factor (G-CSF) in the Mersey and Cheshire Cancer Network
    Mullard, A. P.
    O'Reilly, S. M.
    Ali, Z.
    Schofield, P. S.
    Malik, Z. M.
    Wong, H. C.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S177 - S178
  • [43] Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL)
    Rossi, G
    Donisi, A
    Casari, S
    Re, A
    Stellini, R
    Cadeo, GP
    Carosi, G
    HAEMATOLOGICA, 1998, 83 (04) : 317 - 322
  • [44] Dose-adjusted ABVD plus G-CSF can maintain high relative dose intensity (RDI) and may improve complete response and survival rates in patients with advanced Hodgkin's lymphoma.
    Russo, F
    Celentano, E
    Corazzelli, G
    Frigeri, F
    Svanera, G
    Pinto, A
    BLOOD, 2002, 100 (11) : 305B - 306B
  • [45] Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program
    Worel, Nina
    Rosskopf, Konrad
    Neumeister, Peter
    Kasparu, Hedwig
    Nachbaur, David
    Russ, Gudrun
    Namberger, Konrad
    Witt, Volker
    Schloegl, Ernst
    Zojer, Niklas
    Linkesch, Werner
    Kalhs, Peter
    Greinix, Hildegard T.
    TRANSFUSION, 2011, 51 (05) : 968 - 975
  • [46] High-dose granulocyte-colony stimulating factor (G-CSF) in vitro induces the growth of high proliferative potential colony forming cells (HPP-CFC) in patients undergoing blood stem cell mobilization
    PerezOteyza, J
    Ramos, P
    Testa, NG
    Heinrichs, B
    LopezJimenez, J
    GarciaLarana, J
    Odriozola, J
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (06) : 516 - 520
  • [47] Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients:: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor
    Hernandez, D. E.
    Hernandez, A. E.
    EUROPEAN JOURNAL OF CANCER CARE, 2006, 15 (05) : 493 - 496
  • [48] Immune Reconstitution after Autologous Hematopoietic Cell Transplant (AHCT) in B-Cell Non-Hodgkin Lymphoma (B-NHL) Patients Mobilized with Granulocyte Colony Stimulating Factor (G-CSF), with or without Plerixafor
    Torka, Pallawi
    Wallace, Paul K.
    Zhang, Yali
    Chen, George L.
    Ho, Christine M.
    Balderman, Sophia R.
    Ross, Maureen
    Paiva, Bruno
    Hernandez-Ilizaliturri, Francisco J.
    McCarthy, Philip L.
    Hahn, Theresa E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S155 - S156
  • [49] Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: A prospective, multi-institutional AIDS Clinical Trials Group study (ACTG 149)
    Levine, AM
    Li, P
    Cheung, T
    Tulpule, A
    Von Roenn, J
    Nathwani, BN
    Ratner, L
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 24 (05) : 444 - 450
  • [50] Pre- and postmobilization factors affecting progenitor cell mobilization with intermediate-dose cyclophosphamide and granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients
    Kuittinen, T
    Nousiainen, T
    Mahlamäki, E
    Jantunen, E
    BONE MARROW TRANSPLANTATION, 2003, 31 : S69 - S69
12345